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Background: Iron-induced cardiomyopathy causes most deaths in transfused patients (pts) with β-thalassemia major (TM). Deferasirox (Exjade®) 
was shown to remove cardiac iron in TM pts with mild, moderate and severe cardiac siderosis in a sub-study of the 1-yr multicentre prospective EPIC 
trial, as shown by improved cardiac T2*. Here we report 2-yr data from the extension phase.
Methods: Pts aged ≥10 yrs with cardiac T2* >5-<20 ms by cardiovascular magnetic resonance (CMR), left ventricular ejection fraction (LVEF) 
≥56%, serum ferritin (SF) >2500 ng/mL, MR (R2) liver iron concentration (LIC) >10 mg Fe/g dry weight (dw), and a lifetime minimum of 50 
transfused blood units were included. Deferasirox was initiated at 30 mg/kg/d with subsequent dose adjustments of 5-10 mg/kg/day up to 40 mg/
kg/d. Dose decreases were allowed for safety reasons. Primary endpoint: change in cardiac T2* from baseline (BL) at 2 yrs.
Results: Of 100 patients who entered the 1yr extension, 85 completed and 2-yr CMR data are reported for 81. Mean actual deferasirox dose 
increased from 33.1±3.7 mg/kg/d in the core 1yr phase to 36.1±7.4 mg/kg/d in the extension. Cardiac T2* significantly increased from a BL 
geometric mean of 11.2 to 12.9 after 1 yr (P<0.001) and to 15.3 ms after 2 yrs (P<0.001). After 2 yrs deferasirox therapy, significant increases from 
7.3 to 9.3 ms (P<0.001) and from 14.6 to 19.9 ms (P<0.001) were respectively noted in pts with BL T2* <10 (n=39; severe cardiac siderosis) and 
10-20 ms (n=61; mild-to-moderate cardiac siderosis). Overall, LVEF remained stable throughout the 2-yr study (67.5% at BL; 67.2% at 1 yr 67.8% at 
2 yrs). Drug-related adverse events (AEs; >5%) included increased blood creatinine (n=18), increased alanine aminotransferase (n=4) and increased 
aspartate aminotransferase (n=3). There were no drug-related serious AEs or deaths.
Conclusions: This is the first large prospective study to show 2-yr data on cardiac iron removal for an iron chelator. Deferasirox for up to 2 yrs 
at 30-40 mg/kg/d removed iron from the heart in TM pts with cardiac siderosis and was well tolerated. Statistically significant improvements in 
cardiac T2* over 2 yrs were associated with maintenance of normal cardiac function.
